Lawrence Eichenfield's most recent trade in Verrica Pharmaceuticals Inc was a trade of 16,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Verrica Pharma Inc | Lawrence Eichenfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2026 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Verrica Pharma Inc | Lawrence Eichenfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Forte Biosciences Inc | Lawrence Eichenfield | Director | 20 Aug 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | ||
| Verrica Pharma Inc | Lawrence Eichenfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Verrica Pharma Inc | Lawrence Eichenfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 10,384 | 10,384 | - | - | Stock Option (right to buy) | |
| Verrica Pharma Inc | Lawrence Eichenfield | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 10,384 | 10,384 | - | - | Stock Option (right to buy) | |
| Forte Biosciences Inc | Lawrence Eichenfield | Director | 01 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | ||
| Forte Biosciences Inc | Lawrence Eichenfield | Director | 23 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) |